Enspryng: Neuromyelitis optica spectrum disorder

Enspryng:

Company Name :genetech .Inc

Generic Name: Satralizumab-mwge

Dosage Form: Injection for subcutaneous use. 

Introduction: 

The Enspryng consist of satralizumab-mwge which is used for treating neuromyelitis optica spectrum disorder. The satralizumab-mwge act by inhibiting Interleukin-6(IL-6). 

Therapeutic Use:

Satralizumab-mwge is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patient having anti-aquaporin-4 positive. These should not be given if patient is having any active infection. If patient is indentified anyactive infection then these may cause rise in severity of infection. 

These drug should not administered if patient is having HBV active infection.